News Novo Nordisk partners OpenAI on R&D "transformation" Seeking an R&D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.
News Travere claims first FDA OK in rare kidney disease FSGS Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.
News Revolution rockets on strong pancreatic cancer data Revolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib.
News Alamar, Hemab, Kailera, and Seaport advance IPOs The last few days have seen a flurry of biotech IPO news, with Alamar, Hemab, Kailera, and Seaport all pushing for Nasdaq listings.
News IDEAYA/Servier PKC drug aces uveal melanoma trial Servier $210m bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.
News AI could spare bowel cancer patients from unneeded treatment An AI tool could identify colorectal cancer patients most likely to respond to bevacizumab, which was recently backed for NHS use.
News Australia starts probe into AI infiltration of Medicare The infiltration of Australia's Medicare by an AI agent raises serious questions about patient privacy and the security of confidential pharma data.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
